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Summary
Expression of VP16-CREB, a constitutively active
form of CREB, in hippocampal neurons of the CA1
region lowers the threshold for eliciting the late, per-
sistent phase of long-term potentiation (L-LTP) in the
Schaffer collateral pathway. This VP16-CREB-medi-
ated L-LTP differs from the conventional late phase of
LTP in not being dependent on new transcription.
This finding suggests that in the transgenic mice the
mRNA transcript(s) encoding the protein(s) neces-
sary for this form of L-LTP might already be present
in CA1 neurons in the basal condition. We used high-
density oligonucleotide arrays to identify the mRNAs
differentially expressed in the hippocampus of trans-
genic and wild-type mice. We then explored the con-
tribution of the most prominent candidate genes re-
vealed by our screening, namely prodynorphin, BDNF,
and MHC class I molecules, to the facilitated LTP of
VP16-CREB mice. We found that the overexpression
of brain-derived neurotrophic factor accounts for an
important component of this phenotype.
Introduction
The encoding of new memories in the brain is thought
to depend on long-lasting changes in the strength of*Correspondence: abarco@umh.es
7 These authors contributed equally to this work.
8 Present address: Unit of Behavioral Genetics, NIMH, Building 49,
Convent Drive, MSC Bethesda, Maryland 20892-4405.synaptic connections between neurons, a change that
depends, in turn, on transient or permanent alterations
in specific patterns of gene expression. A number of
transcription factors have been identified that play im-
portant roles during learning-related synaptic plasticity.
Of these, the best-studied factor is the cAMP-respon-
sive element binding protein CREB (reviewed in Barco
et al., 2003; Lonze and Ginty, 2002). There is increased
phosphorylation of CREB following stimuli that produce
memory-related long-term potentiation (LTP) (Bito et
al., 1996) as well as after training on hippocampus-
dependent tasks (Taubenfeld et al., 1999). Similarly, the
late phase of LTP and long-term memory storage cor-
relate with increased cAMP responsive element (CRE)-
dependent gene expression, as monitored via the activ-
ity of a CRE-driven lacZ reporter construct in transgenic
mice (Impey et al., 1996, 1998).
To explore the role of CRE-driven genes in hippocam-
pal synaptic plasticity, we generated transgenic mice
in which we could induce, in a regulated manner and
restricted to forebrain neurons, the expression of VP16-
CREB, a constitutively active CREB protein. In the py-
ramidal cells of the CA1 region, the postsynaptic neu-
rons of the Schaffer collateral pathway, VP16-CREB
binds to CRE sites, regulates transcription of a number
of CREB-dependent genes, and facilitates the estab-
lishment of L-LTP in a transcription-independent way.
Based on these results we proposed a model in which
VP16-CREB activates the transcription of CRE-driven
genes and leads to a cell-wide distribution of proteins
or mRNAs that prime synapses so that even a relatively
weak stimulus will give rise to a long-lasting form of
LTP (Barco et al., 2002).
To identify gene products upregulated in VP16-CREB
mice that are responsible for the rapid consolidation of
the long-term process following even a relatively weak
stimulus, we carried out an analysis of altered gene
expression in the hippocampus of these mice by us-
ing Affymetrix high-density oligonucleotide arrays. We
identified mRNA transcripts differentially expressed in
the hippocampus of transgenic and wild-type mice and
then combined pharmacological and genetic approaches
to investigate the possible contributions of the most
prominent candidate genes in facilitating the L-LTP in
the Schaffer collateral pathway of VP16-CREB mice.
Results and Discussion
Identification of Genes Whose Altered Expression
in the Hippocampus of VP16-CREB Mice
Correlates with the Facilitated L-LTP
in the Schaffer Collateral Pathway
To better characterize the facilitated L-LTP phenotype
of VP16-CREB mice, we carried out a time course
analysis of the onset and reversion of this phenotype.
We found that it was possible to switch transgene ex-
pression on and off in the hippocampus of mutant mice
over the course of a week by controlling the presence
of doxycycline (dox) in the animals’ diet and at the
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124same time that it was possible to regulate the LTP phe-
notype (Figure 1A).
To identify the specific genes whose induction in hip-
pocampal neurons correlated with the facilitated L-LTP
phenotype, we harvested hippocampal mRNA at time
points assessed in our physiological study and carried
out a gene expression analysis with the use of oligonu-
cleotide microarrays. To obtain a sufficient quantity of
poly(A)-RNA and reduce the effect of the biological
variability of the sample, hippocampi from six to ten
mice matched for genotype and time of induction were
pooled together in each sample. The final data set in-
cluded gene chips for animals on dox (gene Off) and
for animals that had been removed from dox (gene ON)
for 1, 2, and 5 weeks. We also included samples from
wild-type mice maintained under identical conditions
and from transgenic mice that expressed VP16-CREB
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lFigure 1. Time Course of Facilitated L-LTP Phenotype and Candidate Genes Induction
Gray boxes indicate the presence of dox in the mouse diet at the time of performing the experiment. Values are presented as means ± SEM.
(A) The appearance of the LTP phenotype correlates with the induction of the VP16-CREB transgene (n = 6 slices [4 mice] per time point).
The graph presents the average amplitude responses 110–130 min after delivering one 100 Hz train stimulation (1 s, 900 pulses). This
stimulation protocol elicits E-LTP in wild-type mice, but L-LTP in VP16-CREB transgenics. (B) Time course of candidate gene upregulation:
we used 81 transgenics and 26 wild-type mice divided into 12 different groups (in average, nine mice per group). The final data set included
gene chips for animals on dox; 1, 2, 3 (microdissected CA1 regions), and 5 weeks after doxycycline removal; mice that expressed VP16-
CREB for 3 weeks before turning transgene off again for 2 weeks (rev), and wild-type littermates (WT, n = 1 because one of the samples from
whole hippocampus and the sample from microdissected CA1 regions were used as baseline). (C) Two-dimensional hierarchical clustering of
ten samples and 73 genes, selected to include only those genes that were consistently changed in VP16-CREB mice after transgene induction
but were unaltered in the different control situations (WT, DOX, and REV). See filter details in Table 1 legend. Two samples corresponding to
wild-type mice (obtained from whole hippocampi or microdissected CA1 regions, respectively) were used for normalization and could not be
included in this clustering.or 3 weeks before turning the transgene off again for
weeks with dox (Rev, gene Off). Because the isolation
f mRNA from the whole hippocampus favors genes
hat are more broadly overexpressed in the hippocam-
us of transgenic mice and, therefore, may lead to an
nderestimation of the total complement of genes
howing an altered expression in specific hippocampal
ubregions, we extended our comparison between
ransgenic and wild-type expression profiles by using
icrodissected CA1 regions. We obtained two samples
orresponding to VP16-CREB mice 3 weeks after in-
uction and one sample corresponding to wild-type
ice kept in the same conditions.
These mRNA samples were analyzed with Affymetrix
ene chips MG-U74v2 setA, which allow the simulta-
eous analysis of 12,654 probe sets representing full-
ength mouse genes and Expressed Sequence Tag
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We filtered and sorted the data through several sequen-
tial analyses by using the GCOS software package from
Affymetrix. The change p value algorithm provides a
measure of the likelihood of change and direction and
is used to generate discrete change calls: I (increase),
MI (marginal increase), NC (no change), D (decrease),
and MD (marginal decrease). In our analysis, we de-
manded that the change call for all of those samples
in which VP16-CREB expression was turned on (seven
samples) indicated a statistically significant change in
expression (i.e., I, MI, D, or MD). In addition, we also
requested that the change call for wild-type samples or
for those samples in which VP16-CREB expression was
turned off was NC. Using this procedure, a surprisingly
small list of only four genes emerged (Figure 1B and
Table 1, first four rows). Notably, among these candi-
dates was CREB itself, two well-known CREB-depen-
dent genes (dynorphin and BDNF), and one MHC class
I antigen.
We sorted these candidate genes using the signal log
ratio (SLR), which estimates the magnitude and direc-
tion of the change. SLR values are expressed as the
log2 ratio of the change in expression level between a
baseline and an experiment array. First on our list, with
the largest change, 13-fold on average, was the probe
set targeted to prodynorphin, a gene that we had pre-
viously identified as being upregulated in VP16-CREB
mice (Barco et al., 2002). In second place, we found a
probe set targeted to CREB that recognizes a se-
quence present in both endogenous CREB and chi-
meric VP16-CREB mRNAs. Because the analysis of
protein extracts from transgenic mice did not show any
apparent change in the level of expression of endoge-
nous CREB (Barco et al., 2002), the upregulation de-
tected by the CREB probe likely corresponds to the in-
duction of VP16-CREB transcripts. We cannot however
exclude some contribution of the endogenous CREB
transcripts, because the CREB promoter contains three
CRE sites that confer positive cis-autoregulation. The
presence of the CREB probe set in this restricted list of
altered genes represented a valuable control that vali-
dated our analysis. The third probe set in our list recog-
nizes transcripts encoding an isoform of MHC class I
antigen. Class I MHC molecules are encoded by a large
and highly homologous gene family whose role in regu-
lating the immune response is well known and that has
more recently also been found to be involved in synap-
tic plasticity (reviewed in Boulanger and Shatz, 2004).
Finally, at the bottom of our list was BDNF. Although
the change in BDNF mRNA was relatively small, it par-
alleled VP16-CREB expression in all of our samples.
Our initial highly restrictive criterion was designed to
identify a small number of VP16-CREB target genes. By
using a less restrictive criterion for sorting the data, we
obtained a larger list of genes affected by the induction
of VP16-CREB (Table 1). The hierarchical clustering of
these probe sets revealed a good correlation between
the altered expression of candidate genes and time af-
ter transgene induction. The clustering also highlighted
the similarity of the expression profiles of samples from
whole hippocampi and microdissected CA1 regions
(Figure 1C). The extended list of candidate genes in-
cluded a number of genes related to neuronal functionand metabolism, such as c-fos, calcyclin, the vesicular
GABA and glycine transporter, and neuropeptide Y. It
is possible that additional genes that are differentially
regulated in VP16-CREB mice escaped our screen be-
cause the microarray MG-U74A does not interrogate
the complete mouse genome.
In a given cell, only a subset of the CRE sites in its
genome is readily available for the binding of CREB and
other CRE binding transcription factors, although the
transactivation activity of bound CREB will remain low
until the cell is exposed to extracellular stimuli that trig-
ger its phosphorylation and the recruitment to the pro-
moter of its coactivator CBP (Lonze and Ginty, 2002).
When the chimeric transcription factor VP16-CREB
binds to these available CRE sites in neurons of trans-
genic mice in the basal conditions, no additional extra-
cellular stimuli are necessary to trigger the transcription
of these promoters. Table 1 should, therefore, include
such a subset of CRE-driven genes. Conversely, those
CRE-driven genes that require additional signals to
converge on their promoter to recruit CREB and trigger
transcription would escape this screening approach.
The information available on the promoters of a num-
ber of candidate genes supports this view. Thus, the
promoter of the Pdyn gene contains three consensus
CRE sites and one nonconventional CRE site (Collins-
Hicok et al., 1994) that participate in the regulation of
the expression of dynorphin both in vivo and in vitro
(Carlezon et al., 1998; Cole et al., 1995). Similarly, the
mouse MHC class I promoter also contains two CRE-
like sequences in the 5# flanking region that are highly
conserved among species and important for the ex-
pression and regulation of MHC class I genes by CREB
(Ishiguro et al., 1998). The BDNF promoter also con-
tains a consensus CRE and CRE-like sequences, and a
number of experiments both in vivo and in vitro have
previously shown that BDNF is regulated by CREB (Ta-
buchi et al., 2002; Tao et al., 1998). One CRE site has
been identified in the promoter of c-fos and three in
that of CREB.
It is also possible that some of the genes detected in
our analysis are indirect targets of CREB. The identifi-
cation of several transcription factors that are upregu-
lated in VP16-CREB mice, including the immediate
early response genes (IEG) c-fos, a well-known gene
induced by neuronal activity, suggests that there may
exist a second wave of transcriptional activation trig-
gered by VP16-CREB induction. Notably, Table 1 also
contains more than a dozen probes targeted to MHC
class I antigen sequences, both classical and nonclas-
sical. In addition to MHC class I antigens, we also found
that other genes related to immune and inflammatory
response were upregulated during the course of our ex-
periment. It is difficult, however, to know whether the
induction of these genes is a direct consequence of the
activity of VP16-CREB or a side effect of the upregula-
tion of MHC I observed at early time points. We are
currently investigating the long-term consequences of
this altered expression on neuronal survival.
Validation of Gene Chip Results
by In Situ Hybridization
We used in situ hybridization to assess the expression
of a number of interesting candidate and control genes.
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126Table 1. Genes with Altered Expression in the Hippocampus of VP16-CREB Mice
SLR ± SD SLR ± SD SLR ± SD SLR ± SD SLR
Score Probe Set Gene Name control(3) 1w(2) 2w(2) 3wCA1(2) 5w(1) Function
0/7 99840_at Prodynorphin 0.5 ± 0.6 2.8 ± 0.5 4.8 ± 0.3 3.0 ± 0.4 4.7 CC, N
0/7 102672_g_at cAMP responsive element binding 0.0 ± 0.1 2.6 ± 0.5 3.7 ± 0.1 3.6 ± 0.5 3.2 TR
protein 1
0/7 98472_at H2-T23: histocompatibility 2. T region 0.1 ± 0.1 0.6 ± 0.2 2.2 ± 0.4 2.8 ± 0.2 2.3 ST
locus 23
0/7 102727_at Brain derived neurotrophic factor 0.0 ± 0.2 0.6 ± 0.2 0.7 ± 0.1 0.7 ± 0.0 0.9 CC, N
0/6 97173_f_at LOC436489: similar to MHC class I-alpha 0.3 ± 0.1 0.6 ± 0.2 2.8 ± 0.4 2.4 ± 2.6 3.7 ST
1/6 103016_s_at CD68 antigen 0.3 ± 0.3 0.3 ± 0.0 1.2 ± 0.1 1.8 ± 0.3 1.3 NA
0/6 96627_at Phenylalkylamine Ca2+ antagonist binding −0.1 ± 0.1 0.0 ± 0.4 0.6 ± 0.1 0.8 ± 0.1 0.4 CM
protein
1/6 93088_at b-2 microglobulin 0.2 ± 0.3 0.3 ± 0.1 0.6 ± 0.2 1.0 ± 0.1 2.0 ST
0/6 98627_at Insulin-like growth factor binding protein 2 −0.2 ± 0.1 0.4 ± 0.1 0.4 ± 0.2 1.0 ± 0.4 0.7 NA
0/6 99669_at Lectin. galactose binding. soluble 1 0.1 ± 0.1 0.4 ± 0.3 0.4 ± 0.1 0.9 ± 0.3 1.1 CD
−1/6 98967_at Fatty acid binding protein 7. brain −0.2 ± 0.4 0.5 ± 0.1 0.2 ± 0.1 1.0 ± 0.1 0.3 T
0/5 100998_at H2-Ab1: histocompatibility 2. 0.0 ± 0.1 1.6 ± 2.0 4.2 ± 0.1 4.7 ± 0.4 4.9 ST
0/5 102424_at Chemokine (C-C motif) ligand 3 1.7 ± 0.1 0.9 ± 0.8 2.4 ± 0.4 2.2 ± 1.5 3.3 CC, ST
0/5 97125_f_at LOC56628: MHC (A.CA/J(H-2K-f) class I 0.6 ± 0.3 0.7 ± 0.1 2.2 ± 0.4 1.1 ± 0.1 2.6 NA
0/5 100621_at Ribonuclease/angiogenin inhibitor 1 0.4 ± 0.8 0.9 ± 0.0 1.8 ± 0.2 1.1 ± 0.3 1.0 NA
1/5 101753_s_at Lysozyme 0.4 ± 1.0 0.1 ± 0.4 1.7 ± 2.1 3.2 ± 0.7 5.9 CM
1/5 94144_g_at Similar to glial fibrillary acidic protein 0.2 ± 0.4 0.1 ± 0.1 1.6 ± 0.1 2.0 ± 0.2 2.3 NA
1/5 100397_at TYRO protein tyrosine kinase binding 0.5 ± 0.4 0.0 ± 0.1 1.5 ± 0.3 1.6 ± 0.1 2.7 NA
protein
0/5 104388_at Chemokine (C-C motif) ligand 9 0.8 ± 0.4 1.0 ± 0.0 1.4 ± 0.2 1.8 ± 0.1 2.3 CC, ST
1/5 160901_at c-fos (FBJ osteosarcoma oncogene) 0.2 ± 0.2 0.7 ± 0.4 1.4 ± 0.0 0.6 ± 0.9 2.5 TR
0/5 99378_f_at LOC436493 (similar to MHC class I, H-2 0.2 ± 0.1 0.6 ± 0.1 1.4 ± 0.2 1.9 ± 0.6 2.3 NA
Q4)
1/5 93120_f_at H2-K1: histocompatibility 2. K1. K region 0.1 ± 0.2 0.2 ± 0.1 1.4 ± 0.2 1.6 ± 0.1 1.9 ST
1/5 94143_at Glial fibrillary acidic protein 0.2 ± 0.5 0.2 ± 0.1 1.4 ± 0.1 1.6 ± 0.4 1.7 C&E
0/5 101502_at TG interacting factor 0.6 ± 0.3 0.8 ± 0.2 1.3 ± 0.4 2.0 ± 0.4 2.2 TR
0/5 93714_f_at Similar to MHC class I −0.2 ± 1.0 0.1 ± 0.4 1.3 ± 0.3 1.6 ± 0.0 1.8 NA
1/5 97540_f_at H2-D1: histocompatibility 2. D region 0.3 ± 0.1 0.2 ± 0.1 1.3 ± 0.1 1.8 ± 0.0 1.8 ST
locus 1
0/5 104606_at CD52 antigen 0.1 ± 0.4 0.2 ± 0.1 1.2 ± 0.3 3.7 ± 0.3 2.7 NA
1/5 94425_at Lymphocyte antigen 86 0.3 ± 0.4 0.0 ± 0.1 1.2 ± 0.0 1.9 ± 0.3 2.0 CC
0/5 102161_f_at H2-Q2: histocompatibility 2. Q region 0.2 ± 0.2 0.2 ± 0.1 1.2 ± 0.4 1.7 ± 0.1 1.6 ST
locus 2
0/5 97541_f_at H2-D1: histocompatibility 2. D region −0.3 ± 0.3 −1.4 ± 0.4 1.1 ± 0.4 1.6 ± 0.1 2.0 ST
locus 1
0/5 98438_f_at H2-Q7: histocompatibility 2. Q region 0.2 ± 0.1 0.2 ± 0.1 1.1 ± 0.3 2.0 ± 0.3 1.8 ST
locus 6
0/5 97687_at EST03336 0.0 ± 0.2 0.4 ± 0.1 1.1 ± 0.1 1.2 ± 0.4 1.1 NA
1/5 97519_at Secreted phosphoprotein 1 0.4 ± 0.5 0.3 ± 0.0 1.0 ± 0.2 2.9 ± 0.6 2.2 CC, ST
0/5 101886_f_at H2-D1: histocompatibility 2. D region 0.2 ± 0.1 0.2 ± 0.1 1.0 ± 0.2 1.8 ± 0.2 1.7 ST
locus 1
0/5 92633_at Cathepsin Z 0.2 ± 0.3 0.1 ± 0.0 1.0 ± 0.0 1.6 ± 0.2 2.1 CM
0/5 93067_f_at Histone 2. H2aa1 0.1 ± 0.2 0.1 ± 0.4 1.0 ± 0.2 0.5 ± 0.6 1.1 NA
1/5 92223_at C1qg (complement component 1g) 0.2 ± 0.2 0.0 ± 0.0 1.0 ± 0.1 1.5 ± 0.1 1.8 CC
1/5 103033_at Complement component 4 (within H-2S) 0.4 ± 0.3 0.2 ± 0.1 0.9 ± 0.3 1.6 ± 0.2 2.6 CC
−1/5 103235_at Neuropeptide Y 0.0 ± 0.3 0.0 ± 0.0 0.8 ± 0.1 0.8 ± 0.3 1.2 CC, ST
0/5 102330_at Allograft inflammatory factor 1 −0.2 ± 0.6 −0.4 ± 1.1 0.8 ± 0.1 1.4 ± 0.2 1.7 S&C
0.5/5 102255_at Oncostatin M receptor 0.1 ± 0.3 0.4 ± 0.1 0.8 ± 0.1 1.0 ± 0.5 1.7 CC, ST
0/5 94238_at RIKEN cDNA 2310046G15 gene 0.2 ± 0.1 0.6 ± 0.1 0.8 ± 0.2 1.0 ± 0.4 1.3 CM
0/5 102955_at Nfil3: nuclear factor. interleukin 3. 0.2 ± 0.3 0.1 ± 0.3 0.8 ± 0.2 0.9 ± 0.0 1.2 CM
regulated
0/5 101420_at Slc32a1 (GABA vesicular transporter) 0.0 ± 0.1 −0.1 ± 0.1 0.7 ± 0.0 0.6 ± 0.4 0.7 T
0/5 160275_at Selenoprotein X 1 0.3 ± 0.2 0.2 ± 0.1 0.7 ± 0.1 0.4 ± 0.0 0.6 CM
0/5 102353_at Integrin b2 −0.3 ± 0.7 0.1 ± 0.1 0.7 ± 0.1 1.6 ± 0.4 0.9 CC, ST
1/5 100012_at Lysosomal-associated protein 0.1 ± 0.3 0.0 ± 0.1 0.6 ± 0.1 1.0 ± 0.4 1.2 NA
transmembrane 5
0/5 97867_at Hydroxysteroid 11-beta dehydrogenase 1 0.1 ± 0.1 0.2 ± 0.0 0.6 ± 0.0 1.1 ± 0.1 0.7 CM
1/5 93875_at Heat shock protein 1A 0.3 ± 0.3 0.2 ± 0.1 0.6 ± 0.0 0.3 ± 0.1 0.5 CM
0/5 92770_at S100 calcium binding protein A6 −0.1 ± 0.1 −0.1 ± 0.1 0.6 ± 0.2 1.2 ± 0.6 1.4 ST
(calcyclin)
1/5 104354_at Csf1r: colony stimulating factor 1 receptor 0.2 ± 0.2 0.0 ± 0.1 0.6 ± 0.1 0.8 ± 0.2 1.2 CC, ST
0/5 104155_f_at Atf3: Activating transcription factor 3 −0.1 ± 0.1 0.2 ± 0.1 0.6 ± 0.1 1.2 ± 0.7 0.9 TR
1/5 95661_at CD9 antigen 0.0 ± 0.3 0.2 ± 0.1 0.5 ± 0.1 1.4 ± 0.1 1.3 CC
0/5 93843_at Dhrs1: dehydrogenase/reductase SDR1 0.1 ± 0.1 0.1 ± 0.1 0.5 ± 0.0 0.9 ± 0.3 0.7 CM
(continued)
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SLR ± SD SLR ± SD SLR ± SD SLR ± SD SLR
Score Probe Set Gene Name control(3) 1w(2) 2w(2) 3wCA1(2) 5w(1) Function
0/5 94276_at Hydroxysteroid (17-beta) dehydrogenase 0.2 ± 0.1 0.4 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.6 CM
12
0/5 103488_at Selectin. platelet (p-selectin) ligand 0.2 ± 0.1 −0.1 ± 0.1 0.4 ± 0.1 0.4 ± 0.0 0.4 CC
0/5 95542_at Tropomyosin 4 −0.1 ± 0.2 0.2 ± 0.1 0.4 ± 0.0 0.8 ± 0.1 0.8 C&E
0/5 101065_at Proliferating cell nuclear antigen −0.1 ± 0.1 0.4 ± 0.1 0.4 ± 0.2 1.0 ± 0.4 1.0 CM
0/5 94831_at Cathepsin B 0.2 ± 0.1 0.0 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.6 CM
1/5 101955_at Heat shock 70kD protein 5 0.2 ± 0.4 0.3 ± 0.4 0.3 ± 0.3 0.8 ± 0.4 0.4 CC, CM
0/5 160228_at RIKEN cDNA 1110019C08 gene 0.3 ± 0.0 0.4 ± 0.1 0.2 ± 0.2 0.5 ± 0.3 0.6 NA
0/5 101060_at Grp58: glucose regulated protein 0.1 ± 0.2 0.6 ± 0.1 0.2 ± 0.2 1.1 ± 0.8 0.6 CM
1/5 94939_at CD53 antigen 0.1 ± 0.6 −0.1 ± 1.0 0.1 ± 0.4 1.4 ± 0.2 1.7 NA
0/-5 103273_s_at Abcc8: ATP-binding cassette C8 −0.3 ± 0.1 −0.3 ± 0.1 −0.6 ± 0.1 −0.6 ± 0.2 −0.6 ST
0/−5 103763_at Ash1-like −0.2 ± 0.1 −0.4 ± 0.0 −0.4 ± 0.4 −0.6 ± 0.3 −0.3 CM
−1/−5 160899_at Purkinje cell protein 4 −0.3 ± 0.2 −0.4 ± 0.2 −0.4 ± 0.1 −0.3 ± 0.1 −0.6 NA
0/−5 92727_at Amyloid beta (A4) precursor protein- −0.3 ± 0.0 −0.1 ± 0.1 −0.4 ± 0.0 −0.7 ± 0.1 −0.5 T
binding A2
−1/−5 92906_at Eph receptor A7 −0.3 ± 0.2 −0.2 ± 0.0 −0.4 ± 0.2 −0.8 ± 0.1 −1.1 CC, ST
−1/−5 104428_s_at Megakaryocyte-associated tyrosine kinase −0.2 ± 0.1 −0.4 ± 0.1 −0.3 ± 0.0 −0.6 ± 0.4 −0.5 CC, CM
−1/−5 103688_at RIKEN cDNA A830006N08 gene −0.0 ± 0.4 −0.4 ± 0.2 −0.2 ± 0.1 −0.5 ± 0.1 −0.8 NA
1/−5 104337_f_at Plakophilin 2 0.0 ± 0.2 −0.6 ± 0.1 0.2 ± 0.1 −0.6 ± 0.3 −0.4 CC
−1/−6 92542_at D4Wsu53e −0.3 ± 0.1 −0.6 ± 0.0 −0.4 ± 0.1 −0.6 ± 0.4 −0.1 NA
−1/−6 93370_at Brain and kidney protein −0.2 ± 0.2 −0.4 ± 0.3 −0.4 ± 0.0 −0.8 ± 0.4 −0.7 ST
Score (control/VC): We assigned the following values to the change calls produced by GCOS: I = 1, MI = 0.5, D = −1, MD = −0.5, and NC = 0.
Then we added up the values obtained for control samples (control, values can rank from –3 to 3) and for samples in which VP16-CREB was
expressed (VC, ranking from –7 to 7). Probe sets showing an altered expression that correlated exactly with the state of transgene activation
should score 0/7 for increased expression or 0/−7 for decreased expression. This table shows those probes with a score for controls
between –1 and 1, and a score for VC < −5 for downregulation or >5 for upregulation. SLR ± SD: Average of signal log ratio values (log2 ratio) ±
standard deviation. Control: samples corresponding to wild-type mice or VP16-CREB mice on dox. 1w, 2w, 3w, 5w: VP16-CREB mice 1, 2, 3,
or 5 weeks after dox removal. The number of samples per experimental group is indicated in brackets. Function: Biological or molecular
functions based in Gene Ontology annotations: CC, cell communication; CD, cell differentiation; CM, cell metabolism; N, neurotransmission;
S&C, structural and cytoskeleton; ST, signal transduction; T, transport; TR, transcriptional regulation; NA, no annotation.We chose candidate genes based on our gene chip
analysis or their previous identification as IEGs poten-
tially regulated by CREB. The genes analyzed included
dynorphin, MHC I genes, c-fos, BDNF, junB, C/EBPb,
nur77, enkephalin, MKP1, and Arc (Figure 2 and data
not shown). Although the result of this analysis was, in
general, consistent with the gene chip data, in the case
of junB the in situ hybridization analysis revealed a
CA1-restricted upregulation that did not pass GCOS
statistical filters.
These experiments revealed an interesting feature of
VP16-CREB-dependent gene expression: the response
of different brain regions to the induction of constitu-
tively active CREB protein was different. For some
genes, such as those encoding MHC I antigens, the re-
gional pattern of expression closely mirrored that of
VP16-CREB, whereas for others the altered expression
was restricted to a subset of cells. Thus, in the case
of prodynorphin, the response in striatal neurons was
amplified in comparison to hippocampal neurons, con-
sistently with the natural pattern of expression of this
gene, higher in striatum than in hippocampus, whereas
IEGs, such as BDNF, c-fos, or junB, were highly ex-
pressed exclusively in the CA1 region of the hippocam-
pus. These results suggest the contribution of epigenetic
mechanisms, such as cell type-specific methylation of
CRE sites, and region-specific transcription factors
working together with CREB on the transcriptional reg-
ulation of these genes.
Functional Validation of Candidate Genes
We next combined pharmacological and genetic ap-
proaches to investigate the role of the three most prom-inent candidate genes (dynorphin, MHC I, and BDNF)
in the enhanced form of L-LTP observed in VP16-CREB
transgenic mice.
Prodynorphin Is Highly Overexpressed in CA1 Cells
of VP16-CREB Mice but Is Not Required
for the Enhanced L-LTP Phenotype
The gene Pdyn encodes prodynorphin, the precursor
of several biologically active opioid peptides known as
dynorphins. Although the role of prodynorphin in con-
trolling pain and responses to stress in the peripheral
nervous system has been studied extensively, its role
in the central nervous system, including its possible
role in learning and memory, is less understood. Two
different modes of action have been suggested for dy-
norphins, one dependent on opioid receptors that is
blocked by the antagonist naloxone, the other depen-
dent on a nonopioid receptor that is resistant to nalox-
one and blocked by NMDA antagonists (Shukla and
Lemaire, 1994). In the granular neurons of the dentate
gyrus, dynorphin plays an inhibitory role in synaptic
plasticity of the mossy fiber (Terman et al., 1994; Wagner
et al., 1993). However, in the Schaffer collaterals termi-
nating in the CA1 region, where κ-opioid receptors are
absent, dynorphin appears to have dual effects on
NMDA synaptic currents, increasing NMDA currents at
low concentrations of dynorphin and decreasing these
currents at high concentrations (Caudle et al., 1994).
To explore further the general role of dynorphin in
hippocampal LTP in the Schaffer collateral pathway, we
first tested the effect of bath-applied dynorphin (1-13)
[Dyn(1-13)], a biologically active form of this neuropep-
tide. We found that Dyn(1-13) did not affect basal syn-
aptic transmission (Figure 3A; 10 min before incubation,
Neuron
128Figure 2. In Situ Hybrization of Candidate
Genes
In situ hybridizations using oligo probes spe-
cific for the indicated genes on brain sagittal
sections from VP16-CREB mice and wild-
type littermates 2 weeks after dox removal.
Sections from wild-type mice injected with
kainic acid 2 hr before sacrificing (KA 2h)
were used as positive control for IEG induc-
tion. Arrows in the central panels indicate
the direction of the expression change. Our
experiments show enhanced expression of
several CRE-dependent genes (such as pro-
dynorphin, MHC I, c-fos, BDNF, and junB);
however, we did not see upregulation of en-
kephalin (also absent in the gene chip
screen). Arc is shown here as negative con-
trol for an IEG gene not affected by VP16-
CREB expression; interestingly, its promoter
does not contain any CRE site. Similar re-
sults were obtained with three independent
sets of animals.percent baseline = 97% ± 3.8%; 20–30 min after Dyn
(1-13) addition, percent baseline = 101% ± 4.9%; p =
0.11) or the duration of LTP induced by one train of 100
Hz stimulation (Figures 3A and 3B; 1–20 min, percent
baseline = 189% ± 17.8% for control and 194% ±
17.6% for Dyn(1-13), p = 0.39; 100–115 min, percent
baseline = 103% ± 2.2% for control and 105.8% ± 3%
for Dyn(1-13), p = 0.11). There was however a transient
increase in the amplitude of LTP after the peptide was
removed from the bathing solution (30–60 min, percent
baseline = 135% ± 10% for control and 156% ± 12.5%
for Dyn(1-13), p = 0.034).
To carry this investigation further, we examined the
consequences of depleting dynorphin. Pdyn knockout
mice (Pdyn−/−) are viable and show no apparent pheno-
typic alterations (Sharifi et al., 2001). We first tested
whether basal synaptic plasticity in the Schaffer collat-
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wral pathway was affected in these mutants and found
hat the stimulus-response curve was similar in wild-
ype and knockout mice (Figure 3C, p = 0.39). Long-
erm depression (LTD) as well as both E-LTP and L-LTP,
nduced, respectively, by 1 Hz stimulation, one train of
00 Hz, or by four trains of 100 Hz stimulation, were
lso unaltered by the dynorphin deficiency (Figure 3D,
TD 60–90 min, percent baseline = 85% ± 4.79% for
ild-type and 86% ± 4.22% for Pdyn−/−; p = 0.11; Figure
E, E-LTP 30–60 min, percent baseline = 123% ± 7.1%
or wild-type and 130% ± 6.2% for Pdyn−/−; p = 0.12;
nd Figure 3F, L-LTP 90–120 min, percent baseline =
71% ± 7.6% for wild-type and 180% ± 5.8% for Pdyn−/−;
= 0.07). Dynorphin therefore does not appear to play
relevant role in these forms of synaptic plasticity in
ild-type animals.
We next tested the consequences of dynorphin de-
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129Figure 3. The Exogenous Addition or the Genetic Suppression of Dynorphin Does Not Affect Normal L-LTP nor Facilitated L-LTP in VP16-
CREB Mice
Exogenous addition of dynorphin (250 nM) had no significant effect either on test fEPSPs generated at CA3-CA1 synapses of wild-type mice
(A) or in the duration of E-LTP induced by a single tetanus of 100 Hz stimulation (B). (C) Input-output curve of fEPSP slope (mV/ms) versus
stimulus (V) at the Schaffer collateral pathway of hippocampal slices from Pdyn−/− and control mice. (D) A 900 pulse train at 1 Hz evoked LTD
in wild-type and mutant animals. (E) A single 100 Hz train (1 s) evoked E-LTP in wild-type and mutant animals. (F) Four 100 Hz train stimulation
leads to L-LTP in both mutant and control mice. (G) In situ hybridization using an oligonucleotide probe specific for dynorphin shows that
Pdyn−/− mice and VP16-CREB/Pdyn−/− double mutants do not express dynorphin mRNA, while VP16-CREB mice highly overexpress this
mRNA in specific forebrain regions. (H) Expression of VP16-CREB favored the persistence of LTP induced by one 100 Hz train, even in the
absence of dynorphin. In all panels, results were presented as means ± SEM.pletion in VP16-CREB mice by crossing VP16-CREB
mice with mice deficient in dynorphin expression. In the
hippocampus of wild-type mice, the expression of dy-
norphin peptides is low in the granular cells of dentate
gyrus and undetectable in CA1 and CA3 regions,
whereas the staining of sections from VP16-CREB mice
revealed that the same CA1 neurons that expressed
VP16-CREB in the nucleus also overexpressed dynor-
phin in the cytoplasm (data not shown). As expected,Pdyn−/− and VP16-CREB/Pdyn−/− double mutants did
not express dynorphin at all (Figure 3G).
Despite a lack of dynorphin expression, the induction
of VP16-CREB in VP16-CREB/Pdyn−/− double mutants
still led to a reduced threshold for L-LTP that was sim-
ilar to that observed in VP16-CREB single mutant mice
(Figure 3H, 60–90 min, percent baseline = 147% ± 6.2%
for VP16-CREB mice and 143% ± 4.5% for VP16-
CREB/Pdyn−/− mutants, p = 0.39), although L-LTP in
Neuron
130double mutants was significantly enhanced during its
early expression (Figure 3H, 1–30 min, percent base-
line = 169% ± 17% for VP16-CREB mice and 205% ±
20% for VP16-CREB/Pdyn−/− mice, p = 0.007). Thus, in
spite of the fact that VP16-CREB greatly increases the
expression of dynorphin, we could not correlate the ac-
tivity of this protein to the LTP phenotype observed in
VP16-CREB mice. The function and consequences of
dynorphin upregulation in the CA1 region remain un-
known.
MHC I Antigens Are Upregulated in Hippocampal
Neurons of VP16-CREB Mice and Are Involved
in L-LTP
Our screen for overexpressed genes in VP16-CREB
mice revealed more than a dozen ESTs encoding MHC
I antigens (Table 1). A role for MHC I molecules in syn-
aptic plasticity was first suggested by an unbiased
screen for genes involved in synaptic plasticity during
development of the visual system (Corriveau et al.,
1998). Based on that study, Shatz and colleagues pro-
posed that MHC I expression had a postsynaptic role
acting as a “synaptic glue” in stabilizing appropriate
synaptic connections, a view consistent with our re-
sults in VP16-CREB mice. A subsequent study by Shatz
and her colleagues examined the synaptic plasticity
and LTP phenotype of mice deficient for MHC I signal-
ing (Huh et al., 2000) and found that in these mutants
the normal segregation of retinal afferent axons in
central targets during development was disrupted and
synaptic plasticity in hippocampal neurons of adult ani-
mals was altered. In particular, LTP in the Schaffer col-
lateral pathway was enhanced and LTD was absent.
Based on these new findings, Shatz and colleagues
elaborated on their model, concluding that MHC I mole-
cules may also promote the elimination, by pruning, of
inappropriate synapses during development and in the
adult. This hypothesis, therefore, suggests that the en-
hanced LTP observed in MHC I- deficient mice reflects
an absence of the normal pruning of synaptic connec-
tions in the hippocampus during development (Huh et
al., 2000).
To identify the MHC I variants expressed in the hippo-
campus of VP16-CREB mice, we performed RT-PCR of
hippocampal mRNA by using primers targeted to a seg-
ment that varies considerably among different class
members of the MHC I antigen family (see Table S1 in
the Supplemental Data available online). We found that
both wild-type and transgenic mice expressed multiple
MHC I antigens in hippocampal neurons, although the
level of expression for the different MHC I subfamilies,
both classical and nonclassical, was higher in mutant
mice (Figure 4A and data not shown).
As a first step in exploring the possible contribution
of alterations in MHC I to the facilitated L-LTP observed
in VP16-CREB mice, we analyzed the response to 100 Hz
stimulation in the Schaffer collateral pathway of CD3δ−/−
mice (Love et al., 1993), one of the two MHC I-deficient
strains used in Huh et al.’s study. CD3δ is a component
of the class I MHC receptor that is expressed in many
cell types, including neurons, and its depletion disrupts
MHC I signaling. We found that a standard 100 Hz teta-
nus train of 1 s duration, which produces a nonsaturat-
ing short-lasting LTP (E-LTP) in wild-type mice, evoked
an enhanced and subtained form of LTP in CD3d−/− mu-
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mants (Figure 4C, first 5 min, percent baseline = 167% ±
% for wild-type mice and 196% ± 14% for CD3d−/−
ice, p = 0.026; at 2 hr, percent baseline = 106% ± 2%
or wild-type mice and 157% ± 6% for CD3d−/− mice,
= 0.0001). By contrast, the stimulus-response curve
as not significantly altered in knockout mice (Figure
B, p = 0.35). This enhanced response to 1 × 100 Hz
timulation is consistent with the enhanced response
o 4 × 100 Hz stimulation reported by Huh and col-
eagues and attributed by them to the absence of prun-
ng of synaptic connections during development. Since
-LTP is already facilitated in MHC I-deficient mutants,
he introduction of VP16-CREB into a MHC I-deficient
ackground would be unlikely to reveal additional infor-
ation about the contribution of MHC I molecules to
he enhanced phenotype. The exploration of the conse-
uences of MHC I disruption on enhanced LTP in VP16-
REB mice will require the generation of mutant mice
n which MHC I deficiency occurs in the adult brain,
hus bypassing the developmental consequences of its
arly disruption.
MHC I antigens are expressed at low levels in the
renatal hippocampus, but their expression increases
s hippocampal neurons mature, and these molecules
ay come to play a role in modulating adult synaptic
lasticity (Boulanger et al., 2001). Although under nor-
al circumstances the blood-brain barrier prevents the
ntry of leukocytes, antibodies, complement factors,
nd cytokines into the parenchyma of the brain, a sig-
ificant increase in MHC I expression, such as in individ-
als with chronic epilepsy or after prolonged VP16-CREB
xpression, might make the expressing neurons more
usceptible to destruction by invading cells of the im-
une system. The presence of cytokine mRNAs and
ther transcripts related to inflammatory processes in
amples of VP16-CREB mice may reflect this phenome-
on (Table 1).
DNF: A Key Component of the Enhanced LTP
riven by VP16-CREB
he identification of BDNF in our unbiased screen for
enes that are important in late-phase LTP reinforces
he already strong evidence supporting a critical role
or BDNF in some forms of L-LTP. Inhibition of endoge-
ous BDNF or of the signaling through its TrkB receptor
mpairs the late phase of some forms of LTP, indicating
hat BDNF is required for its full expression (reviewed
n Lu, 2003). Furthermore, BDNF expression increases
fter induction of LTP in the CA1 region of the hippo-
ampus and after learning-related events (Lu, 2003;
atterson et al., 1992).
The genomic structure of the BDNF gene is unusually
omplex. This gene contains multiple promoters that
rive the expression of transcripts bearing different
oncoding exons spliced upstream of a common 3#
xon that encompasses the entire encoding sequence.
he detailed characterization of the rat BDNF gene has
evealed the existence of at least four promoters lo-
ated upstream of these alternatively spliced exons
hat enable a precise regulation of BDNF expression in
ifferent cell types or in response to different stimuli
Timmusk et al., 1993). The structure of the mouse gene
s very similar to that of rat (93% homology), but the
ouse gene appears to contain an additional promoter
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131Figure 4. The Expression of Multiple MHC I Genes Is Upregulated in VP16-CREB Mice
(A) In situ hybridization analysis reveals the overexpression of two different MHC I variants in the hippocampus (upper panels) of a VP16-
CREB mouse. Lower panels show a higher-magnification image of the CA1 region. (B) Input-output curve of fEPSP slope (mV/ms) versus
stimulus (V) at the Schaffer collateral pathway of hippocampal slices from CD3d −/− and control mice. (C) A single 100 Hz train evoked L-LTP
in CD3d −/− mice. Values are presented as means ± SEM.and alternative exon located in a sequence homolo-
gous to rat intron II (Martinowich et al., 2003).
To identify the BDNF transcripts upregulated by
VP16-CREB, we carried out a quantitative RT-PCR
analysis with primer pairs specific for each one of the
five upstream exons (Figure 5A). We found that the ex-
pression of mRNAs bearing exons 1, 2, and 3 were sig-
nificantly increased in VP16-CREB mice whereas the
expression of exons 4 and 5 were not affected (Figure
5B). Interestingly, exons 1, 2, and 3 are clustered within
1.5 kb at the 5# end of the gene and 15 kb apart from
exons 4 and 5. The analysis of the genomic sequence
upstream of exon 1 has revealed the existence of regu-
latory elements responsible for the Ca2+-mediated acti-
vation of PI (Tabuchi et al., 2000), including a CRE site
that overlaps with a USF binding element (Tabuchi et
al., 2002). CRE elements have also been reported up-
stream of PII, although their functionality has not been
confirmed (Hayes et al., 1997). Previous studies on the
rat BDNF gene suggested that the promoters PI and PII
shared common regulatory elements. Indeed, a neural-
restrictive silencer element (NRSE) located in intron 1
contributes to the regulation of both promoters (Tim-
musk et al., 1999). Because the molecular interactionsthat underlie the activation of transcription by VP16-
CREB and phospho-CREB are different, the transacti-
vation driven by the VP16 domain might have a broader
range than that of CREB. It is therefore possible that
the binding of VP16-CREB to the CRE element in PI
also activates the expression driven by promoter PII
and even PIII, which are located relatively close down-
stream of a functional CRE site but have not been pre-
viously reported as being regulated by CREB. Strik-
ingly, we did not detect any effect of VP16-CREB
expression on the expression of BDNF driven by pro-
moter PIV, in spite of the presence of a conserved CRE
site upstream of this promoter (Shieh and Ghosh, 1999;
Tao et al., 1998). Experiments in rat neuronal cultures
have found that membrane depolarization induces the
transcription from both P1 and PIII (PIV in the mouse).
Some of these experiments suggest that PIII responds
to depolarization but not to an increase of internal
cAMP (Tao et al., 2002), suggesting that the activation
of CREB is not sufficient to drive rat BDNF PIII expres-
sion, a view that might explain our negative results for
mouse promoter PIV.
To evaluate the component of the facilitated L-LTP in
VP16-CREB mice that is due to an enhanced expres-
Neuron
132Figure 5. VP16-CREB Induces the Expression of BDNF Exons 1, 2,
and 3
Real-time quantitative PCR was used to measure the expression of
BDNF transcripts bearing the differentially regulated exons 1 to 5
in VP16-CREB mice 2 weeks after dox removal from the diet. (A)
Schematic representation of the BDNF gene. The different exons
are indicated by open boxes. Black arrows represent the different
promoters, while the upper open arrows indicate the location of the
different oligos used in this study. Black boxes represent the CRE
sites upstream of promoters PI and PIV. (B) We found that the ex-
pression of exons 1, 2, and 3 were significantly upregulated in
VP16-CREB mice, whereas the expression of exons 4 and 5 were
not affected. Values are presented as means ± SEM. The amplifica-
tion of a sequence located on the coding sequence (CS) common
to all BDNF transcripts confirmed the upregulation detected in the
Affymetrix analysis. Asterisks indicate significant differences from
the control (*p < 0.05; **p < 0.005).
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psion of BDNF we carried out two experiments. First, we
incubated hippocampal slices from VP16-CREB mice
and from wild-type littermates with the BDNF scaven-
ger TrkB receptor body (TrkB-Fc). This protein scav-
enges unbound BDNF and blocks its interaction with
cellular receptors. Although we observed normal E-LTP
in wild-type mice in the presence of this protein (Figure
6A, 30–60 min, percent baseline = 146% ± 9.8% for
control and 141% ± 16 for TrkB-Fc, p = 0.17), the late
expression of the enhanced LTP of VP16-CREB mice
was significantly reduced after incubation with TrkB-Fc
(Figure 6B, 30–60 min, percent baseline = 189% ± 6.1%
for control and 160% ± 12 for TrkB-Fc, p = 0.025).
Second, we crossed BDNF heterozygous mice
(BDNF+/−), in which expression of BDNF mRNA is re-
duced to about half the level of wild-type mice (Ernfors
et al., 1994), with VP16-CREB transgenics. Unlike the
experiments with Pdyn−/− and CD3d −/− mice, we could
not use BDNF homozygous mutants (BDNF−/−), due to
the early mortality and severe developmental problems
of these mice. The reduction in BDNF levels in BDNF+/−
mice did not alter the stimulus-response curves of
either BDNF+/− or VP16-CREB /BDNF+/− mice (Figures
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sC and 6D). Similarly to our experiments using TrkB-Fc,
e found that genetic reduction of BDNF expression
argely blocked the enhanced LTP phenotype observed
n VP16-CREB mice but did not affect E-LTP in wild-
ype mice (Figure 6E, 3 hr post-tetanus, percent base-
ine = 134% ± 11% for wild-type mice and 135% ± 18%
or BDNF+/− mice, p = 0.98; Figure 6F, 3 hr post-tetanus,
ercent baseline = 186% ± 21% for VP16-CREB mice
nd 126% ± 9% for VP16-CREB/BDNF+/− mice, p <
.03).
These two experiments taken together strongly indi-
ate that a significant component contributing to the
-LTP phenotype of VP16-CREB mice results from
verexpression of BDNF.
Predicted Role of BDNF in Synaptic Capture
n our earlier study of the VP16-CREB mice, we pro-
osed that the activity of constitutively active CREB led
o a cell-wide distribution of CRE-driven gene products
n the postsynaptic CA1 neuron that primed the syn-
pses for subsequent synapse-specific capture of L-LTP
y a single tetanus, so giving rise to the facilitated
-LTP phenotype. Here, we have shown than BDNF is
ne of these CRE-driven gene products and can, by
tself, be responsible for an important component of the
acilitated L-LTP. Because facilitated L-LTP in VP16-
REB mice can be equivalent in molecular terms to
ynaptic capture mediated L-LTP in wild-type animals
Barco et al., 2002; Frey and Morris, 1997), BDNF may
lso contribute to the processes of synaptic tagging
nd capture in normal mice. To test this prediction, we
arried out two-pathway experiments in slices of BDNF
eterozygous mice. We stimulated two independent in-
uts (S1 and S2) to the same CA1 neuronal population
nd found that synaptic capture was dramatically im-
aired in BDNF+/− mice (Figure 7A, S2, wt: 120–150
in = 147% ± 9%; BDNF+/−: 114% ± 7%, p = 0.01),
hile 4 × 100 Hz L-LTP was normal (Figure 7A, S1, wt:
20–150 min = 147% ± 12%; BDNF+/−: 145% ± 18%,
= 0.88).
To further explore the role of BDNF in synaptic cap-
ure, we used mice in which the genetic deletion was
estricted either to the entire forebrain, including both
he CA3 and CA1 pyramidal neurons of the hippocam-
us, or only to the postsynaptic CA1 neurons. Thus, we
ould assess the individual contributions of pre- and
ostsynaptic sources of BDNF. We found that both
ypes of BDNF mutants had normal 4 × 100 Hz-induced
-LTP in S1 but exhibited a defect in synaptic capture
n S2 (Figures 7B and 7C). This defect was more pro-
ounced in the case of the forebrain BDNF−/−(CA3-
A1) mutants, suggesting that BDNF may play a dual
ole in synaptic capture. First, the decay of the late
hase observed in the more restricted BDNF−/−(CA1)
utants suggests a late, postsynaptic role in the main-
enance of captured L-LTP (Figure 7C, S2 3 hr after
timulation: 150% ± 7% for wild-type mice and 130% ±
% for BDNF−/−(CA1) mice, p = 0.044), a view consis-
ent with our results in VP16-CREB and BDNF+/− mice,
ith the facilitation of the late phase of LTP by exoge-
ous BDNF (Kovalchuk et al., 2002) and with the late
nhancement of BDNF expression observed in post-
ynaptic CA1 neurons after L-LTP induction (Patterson
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133Figure 6. Pharmacological or Genetic Suppression of BDNF Reverses the Facilitated L-LTP Phenotype of VP16-CREB Mice
(A) Exogenous addition of TrkB-Fc had no effect on either test fEPSPs generated at CA3-CA1 synapses (inset) or E-LTP induced by a single
tetanus of 100 Hz stimulation in wild-type mice. (B) Exogenous addition of TrkB-Fc had not effect on test fEPSPs generated at CA3-CA1
synapses (inset) but reduced the amplitude of facilitated L-LTP induced by a single tetanus of 100 Hz stimulation in VP16-CREB mice. (C and
D) Input-output curves of fEPSP slope (mV/ms) versus stimulus (V) at the Schaffer collateral pathway of hippocampal slices from BDNF+/−
and control mice or VP16-CREB/BDNF+/− double mutant and VP16-CREB mice. (E) Normal E-LTP induced by a single 100 Hz train in BDNF+/−
and control mice. (F) Facilitated L-LTP evoked by a single 100 Hz train is reduced in VP16-CREB/BDNF+/− double mutants. In all panels,
results are presented as means ± SEM.et al., 1992). Second, the rapid decay of captured LTP
in slices lacking presynaptic BDNF (Figure 7B, S2 3 hr
after stimulation: 161% ± 21% for wild-type mice and
113% ± 8% for BDNF−/−(CA3-CA1) mice, p = 0.019)
suggests that the presynaptic release of BDNF into the
synaptic cleft after tetanic stimulation may participate
in the postsynaptic tagging of the synapse.Although the role of BDNF in hippocampal LTP has
been extensively studied, some aspects of its function
are just beginning to be understood. For example,
BDNF seems to participate only in some forms of LTP
(Korte et al., 1995; Korte et al., 1998; Patterson et al.,
1996, 2001; Zakharenko et al., 2003). Also, the presyn-
aptic or postsynaptic source of BDNF and its cellular
Neuron
134Figure 7. Synaptic Capture in BDNF-Deficient Mice
(Inset) Drawing of a hippocampal slice showing the positioning of the electrodes. Recordings in S1 are represented in the left panels, and
recording in S2 are represented in the rigth panels. (A) In wild-type mice, the formation of L-LTP in S1 enables the induction of L-LTP in S2
by 100 Hz stimulation. BDNF+/− mice showed a deficit in both the initial amplitude and the duration of synaptic capture-mediated LTP in S2.
(B) Genetic disruption of BDNF in the CA3 and CA1 regions of the hippocampus significantly reduces the amplitude and duration of synaptic
capture-mediated LTP in S2 but does not affect noticeably the expression of L-LTP in S1. (C) Genetic disruption of BDNF only in CA1
postsynaptic neurons does not affect the initial amplitude of synaptic capture-mediated LTP in S2 but reduces its late phase. In all panels,
results are presented as means ± SEM.targets in different forms of LTP are only now being de-
lineated (Manabe, 2002; Zakharenko et al., 2003). Our
study further clarifies these issues in two ways (Figure
8). First, similarly to experiments using exogenously ap-
plied BDNF (Kovalchuk et al., 2002), the experiments in
VP16-CREB mice suggest that, regardless of the site of
BDNF release, increased levels of BDNF in the synaptic
cleft lead to a facilitation of LTP in CA3-CA1 synapses,
probably by acting on both pre- and postsynaptic tar-
gets. An enhanced release of BDNF accumulated in
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ppostsynaptic spines of CA1 neurons of VP16-CREBice after tetanic stimulation may contribute to sus-
aining an otherwise transient potentiation by stimulat-
ng local protein synthesis (Aakalu et al., 2001; Kang
nd Schuman, 1996) or enhancing the neurotransmitter
elease from presynaptic CA3 neurons (Tyler et al.,
002; Tyler and Pozzo-Miller, 2001; Zakharenko et al.,
003). Second, our experiments on synaptic capture
uggested distinct roles for pre- or postsynaptically re-
eased BDNF. Interestingly, a recent study in neuronal
rimary cultures has demonstrated that BDNF-inducedplasticity exhibits a bimodal profile and has an early
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135Figure 8. L-LTP Facilitation in VP16-CREB
Mice and the Various Roles of BDNF in Syn-
aptic Plasticity
The release of BDNF into the synaptic cleft
by the pre- or postsynaptic neuron can stim-
ulate different functions in both the pre- and
postsynaptic terminal. Induction of NMDAR-
dependent LTP enhances the release of
BDNF, which participates in diverse cellular
mechanisms related to the maintenance of
LTP, such as the stimulation of local protein
synthesis in the synapse, the enhancement
of neurotransmitter release by the presynap-
tic neuron, and the activation of transcription
in the nucleus of the postsynaptic neuron.
These processes contribute to the perpetua-
tion of the, otherwise transient, strengthen-
ing of synaptic connections in some forms of
LTP. VP16-CREB mice exhibit an enhanced
expression of BDNF transcripts bearing ex-
ons 1, 2, or 3 in postsynaptic CA1 neurons
that enables the rapid establishment of the
late phase of LTP observed in these animals.
Our results also suggest a role of presynapti-
cally released BDNF in the postsynaptic tag-
ging of the synapse.presynaptic component and a later postsynaptic com-
ponent (Alder et al., 2005). Our results indicate that a
similar bimodal action can be also observed in hippo-
campal slices. Thus, presynaptically released BDNF
contributes to the formation of those forms of LTP that
recruit a presynaptic component (Zakharenko et al.,
2003) and might participate in tagging the synapse for
subsequent capture of late-phase LTP (this study),
while postsynaptically released BDNF might contribute
to the maintenance of different forms of L-LTP at late
times (Korte et al., 1998; Patterson et al., 2001), includ-
ing facilitated L-LTP in VP16-CREB mice and synapti-
cally captured L-LTP.
Concluding Remark
LTP is not a unitary phenomenon, but a family of dif-
ferent processes. It is most likely for this reason that
hundreds of molecules and more than a dozen molecu-
lar pathways have been implicated in the induction, ex-
pression, and maintenance of the family of LTP pro-
cesses. The list of candidate genes revealed by this
study suggests the existence of complex interactions
between various gene networks. Nevertheless, our
analysis provides insights into the molecular mecha-
nism underlying a specific aspect of the phenotype of
VP16-CREB mice: their enhanced L-LTP in the Schaffer
collateral pathway. We found that the overexpression
of BDNF by itself importantly contributes to the L-LTP
phenotype of VP16-CREB mice and that reducing
BDNF compromises the phenotype. Further physiologi-
cal studies might reveal the contribution of other candi-
date genes to other aspects of the complex phenotype
of VP16-CREB mice and explain the causes and conse-
quences of their altered expression.
Experimental Procedures
Generation and Maintenance of Transgenic Mice
Generation of pCaMKII-tTA, tetO-VP16-CREB, Pdyn−/−, CD3d−/−,
+/− −/− −/−BDNF , BDNF (CA3-CA1), and BDNF (CA1) mutant mice has
been described before (Barco et al., 2002; Ernfors et al., 1994; Loveet al., 1993; Mayford et al., 1996; Sharifi et al., 2001; Zakharenko et
al., 2003). We designated as VP16-CREB mice those bitransgenic
animals that resulted from the crossing of pCaMKII-tTA (line B) and
tetO-VP16-CREB (line VC27) mice. In experiments using VP16-
CREB mice, dox was administrated at 40 mg/Kg of food and was
removed at specific times before experimentation. Mice were main-
tained and bred under standard conditions, consistent with NIH
guidelines and approved by the IACUC.
Microarrays
Total RNA was extracted from dissected hippocampi or microdis-
sected CA1 regions using TRIzol (Invitrogen) according to the man-
ufacturer’s protocol. PolyA mRNA was then isolated using Mes-
sagemaker kit (Pharmacia). cDNA synthesis and cRNA production
and fragmentation were carried out as described in the Expression
Analysis Technical Manual (Affymetrix). U74Av2 gene chips were
hybridized, stained, washed, and screened for quality according to
the manufacturer’s protocol. The Affymetrix gene chip data were
processed, normalized, and statistically analyzed using GCOS 1.2
software. The TGT value chosen for the normalization was 500, and
each array was normalized according to its baseline (mRNA from
the hippocampus or microdissected CA1 regions of wild-type litter-
mates). The scaling factor after normalization was comparable in
all arrays. I, D, MI, MD, and NC calls where obtained according to
the change threshold defined by the software. We filtered and
sorted the list of genes using the change p value, change call, and
log ratio signal as described in the text and figure legends. Subse-
quent agglomerative hierarchical clustering analysis was per-
formed using the Spotfire DecisionSite for Functional Genomics
software (Somerville, MA). We used the UPGMA (unweighted
average) clustering method and based the measure of similarity on
euclidean distances. Function annotations in Table 1 were gener-
ated using the gene ontology browser tool included in the SpotFire
software and the ontology information available in NetAffx analy-
sis center.
In Situ Hybridization and Quantitative RT-PCR
Radioactive in situ hybridization was performed as described in
Wisden and Morris (1994) with [33P]ATP-labeled oligonucleotides.
MHC I transcripts were also detected using DIG-labeled RNA
probes and a Tyramide signal amplification kit (Molecular Probes,
Eugene, OR). qPCR was carried out in an Applied Biosystems 7300
real-time PCR unit using the SYBR Premix ex Taq mix (Takara) and
primers specific for the different BDNF exons (Table S2). Each inde-
pendent sample was assayed in triplicate and BDNF levels were
normalized using GAPDH.
Neuron
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Hippocampi were collected following cervical dislocation of 3- to
4-month-old mice of either sex. Transverse hippocampal slices
(400 m) were incubated in an interface chamber at 27°C–28°C,
subfused with oxygenated artificial cerebrospinal fluid (ACSF, con-
taining 119 mM NaCl, 4.0 mM KCl, 1.5 mM MgSO4, 2.5 mM CaCl2,
26.2 mM NaHCO3, 1 mM NaH2PO4, and 11 mM mM glucose), and
allowed to equilibrate for at least 2 hr. Field excitatory postsynaptic
potentials (fEPSP) from the CA1 area were recorded from apical
dendrites by placing both stimulating and recording electrodes in
the stratum radiatum. Two-pathway experiments were performed
by placing two stimulating electrodes and one recording electrode
within the stratum radiatum of the CA1 area (see scheme in Figure
7A). The recording electrode could separately detect fEPSPs gen-
erated by the activation of the independent pathways activated by
each stimulating electrode. We confirmed pathway independence
by testing paired-pulse facilitation between each set of afferents
(data not shown). Before each experiment, synaptic input/output
curves were generated, and the stimulation intensity was adjusted
to give fEPSP slopes of approximately 30%–40% of maximum.
Baselines were sampled once per minute at this intensity (test
pulse, 0.05 ms duration). E-LTP and L-LTP induction protocols con-
sisted, respectively, of one or four (with 5 min intertrain intervals) 1
s train at 100 Hz. the LTD induction protocol consisted of one train
of 900 pulses at 1 Hz. When indicated, ACSF was supplemented
with dynorphin 1-13 (Sigma) or TrkB-Fc (generous gift of Regen-
eron). All the electrophysiology experiments, except the time
course in Figure 1A, were carried out 2 weeks after dox removal.
At this time postinduction, two-photon microscopy confirmed that
spine morphology in CA1 neurons was normal in VP16-CREB mice
(C. Lang et al., personal communication). Two-way ANOVA and Stu-
dent’s t test were used for data analysis. In the text, the electro-
physiological data are presented as mean ± SD, whereas in the
figures the values are presented as mean ± SEM and the number
of tested slices is indicated in brackets. Experimenters were blind
to mice genotype.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/48/1/123/DC1/.
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